Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00774696 · ClinicalTrials.gov registry record · NA
Bioequivalence Study of Clarithromycin 500 mg Tablets Under Non-Fasting Conditions
A NA study, sponsored by Ranbaxy Laboratories Limited.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT00774696: Completed NA study, sponsored by Ranbaxy Laboratories Limited.
NCT00774696 is a NA study that has completed, run by Ranbaxy Laboratories Limited. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00774696, a NA study, has completed, sponsored by Ranbaxy Laboratories Limited.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
The objective of this study is to compare the relative bioavailability of clarithromycin 500 mg tablets (Ranbaxy Laboratories Limited) with that of BIAXIN® 500 mg tablets in healthy, adult subjects under non-fasting conditions.
Interventions
- DRUG clarithromycin 500mg tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2002-12 |
| Est. Completion | 2003-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00774696
The ClinicalTrials.gov registry entry for NCT00774696 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ranbaxy Laboratories Limited, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which clarithromycin 500mg tablets is the first listed.
NCT00774696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00774696 about?
NCT00774696 is a clinical study titled "Bioequivalence Study of Clarithromycin 500 mg Tablets Under Non-Fasting Conditions". The objective of this study is to compare the relative bioavailability of clarithromycin 500 mg tablets (Ranbaxy Laboratories Limited) with that of BIAXIN® 500 mg tablets in healthy, adult subjects under non-fasting conditions.
What is the current status of trial NCT00774696?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2002-12. Estimated completion is 2003-02.
What interventions are being tested in trial NCT00774696?
The interventions under investigation include: clarithromycin 500mg tablets (DRUG).
Who is sponsoring clinical trial NCT00774696?
This trial is sponsored by Ranbaxy Laboratories Limited, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.